Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Craig Gower"'
Autor:
Yusuke, Narita, Takuya, Yoshimoto, Tomoyuki, Namai, Takashi, Asakawa, Satoe, Kawakami, Craig, Gower-Page, Irmarie, Reyes-Rivera, Arisha, Patel, Yoshiaki, Nakamura
Publikováno v:
JCO clinical cancer informatics. 6
We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 (A noninterventional study was conducted using patient-level data from MyPathway participants receiving PER-HER and real-world patients withThe PER-HER arm co
Autor:
Yusuke Narita, Takuya Yoshimoto, Tomoyuki Namai, Takashi Asakawa, Satoe Kawakami, Craig Gower-Page, Irmarie Reyes-Rivera, Arisha Patel, Yoshiaki Nakamura
Publikováno v:
JCO Clinical Cancer Informatics.
PURPOSE We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 ( HER2)–amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving pertuzumab plus trastuzumab (PER-HER) in the phase IIa MyPathw
Autor:
Carsten Schröder, Craig Gower-Page, Irmarie Reyes-Rivera, Arisha Patel, Richard Price, Shiraj Sen, Jessica Davies, Emily Castellanos, Jeremy Snider, Xiaobo Bai, Virginia Fisher, Shivani K. Mhatre
Publikováno v:
JCO clinical cancer informatics. 6
PURPOSE The molecular heterogeneity of metastatic colorectal cancer (mCRC) presents a therapeutic challenge, with few trials focused on patients with human epidermal growth factor receptor 2 amplification (HER2-Amp). Our limited understanding of real
Autor:
Alexandra Bazeos, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer, Anna-Maria Fink, Barbara Eichhorst, Nadine Kutsch, Kathryn Humphrey, Clemens-Martin Wendtner, Julia von Tresckow, Günter Fingerle-Rowson, Sandra Robrecht, Paula Cramer, Othman Al-Sawaf, Craig Gower, Petra Langerbeins, Valentin Goede, Jasmin Bahlo
Publikováno v:
American Journal of Hematology. 94:1002-1006
In CLL, progressive disease (PD) following remission after first line treatment can present with varying phenotypes. We hypothesized that the mode of PD correlates with clinical outcomes. Data from three phase III trials of the German CLL Study Group
Publikováno v:
Journal of Open Source Software. 7:4251
Autor:
Takuya Yoshimoto, Yusuke Narita, Miho Yuki, Takashi Asakawa, Satoe Kawakami, Craig Gower-Page, Irmarie Reyes-Rivera, Arisha Patel, Yoshiaki Nakamura
Publikováno v:
Journal of Clinical Oncology. 40:36-36
36 Background: ML28897 (MyPathway) is a multi-basket trial evaluating the efficacy and safety of targeted therapies in non-indicated tumor types harboring relevant genetic alterations. In MyPathway, patients with treatment-refractory HER2-amplified m
Autor:
Kathryn Humphrey, Alexandra Bazeos, Francine Swann, Nelson Kinnersley, Othman Al-Sawaf, Noelle Crompton, Craig Gower, Günter Fingerle-Rowson, Peter Trask, Mark Dixon, Valentin Goede
Publikováno v:
Blood. 128:4352-4352
BACKGROUND The evaluation of response to therapy in CLL is widely assessed according to the iwCLL guidelines which define progressive disease (PD) as advancing lymphocytosis, lymphadenopathy, organomegaly, cytopenias or histological transformation (H